Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adult patients. GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is an opioid analgesic that acts on the central nervous system to relieve pain. It is used in several clinical situations:

- Acute postoperative pain: provides effective relief after surgical procedures. - Cancer‑related pain: helps control moderate to severe pain associated with malignancies. - Chronic musculoskeletal pain: used when other analgesics are insufficient. - Neuropathic pain: may be prescribed as part of a multimodal regimen for nerve‑related pain. - Severe trauma pain: offers analgesia for injuries requiring strong pain control.

Tapentadol may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: feeling light‑headed or unsteady. - Constipation: reduced bowel movements. - Headache: mild to moderate head pain. - Somnolence: increased sleepiness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: risk of convulsive episodes, particularly at high doses. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Opioid dependence: potential for misuse or addiction. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Tapentadol, clinicians should consider several safety measures:

- Assess pain severity: confirm that the pain level warrants an opioid analgesic. - Evaluate opioid history: review any prior opioid use or dependence. - Monitor respiratory function: watch for signs of respiratory depression, especially after dose initiation. - Adjust for renal/hepatic impairment: dose may need modification in patients with liver or kidney dysfunction. - Avoid concomitant CNS depressants: limit use of alcohol, benzodiazepines, or other sedatives. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Tapentanol may  

Major  Interactions (​​​  ) : -   -    bsp  \\  

g  t  \\\